Bayer interception and Vividion IPO

Create_time:2021-08-05 Views:343


Today, the German pharmaceutical company Bayer announced that it will acquire Vividion, an early preclinical biotechnology company, for 1.5 billion in cash and 500 million miles. This is the second time Bayer intercepts the upcoming IPO of biotechnology after acquiring the stem cell company AskBio last year for 4 billion. company. Vividion originally planned to be listed on the Nasdaq this year, but after hearing the news, Bayer completed the acquisition of Vividion within 7 weeks after hearing the news. Vividion’s main platform is the development of irreversible inhibitors for difficult-to-drug targets and the discovery of new targets. Now the product line is some high-risk early assets, such as transcription factors Nrf2, Stat3 and DNA helicase WRN inhibitors/activators Wait.

Drug source analysis

It is extremely difficult to develop these assets of Vividion to a level that can enter the clinic. So how can such early and high-risk assets be worth 2 billion? The answer is that the founders of Vividion are today's top scientists. Ben Cravatt is not only one of the best chemical biologists, his understanding of drug design and optimization is better than any senior industrial scientist, and his overall view is absolutely top-notch. The ABPP technology he invented is crucial for target discovery. Two years ago, he designed 8 pairs of enantiomers to find active ligands for 176 proteins in the entire proteome. Phil Baran is the most outstanding synthetic chemist in the past 20 years. The synthetic route designed by the general outstanding chemist is breathtaking, and it was a compliment that the molecule synthesized itself by itself. The route designed by Baran is confusing. If a graduate student designed it in this way, he would be considered that chemistry was taught by a physical education teacher. Yu Jinquan is one of the most outstanding explorers of synthetic methodology. The two of them also pay great attention to the practicality of chemistry and are top masters in finding new molecular frameworks.

Yigao people are bold, and Vividion product lines are all targets that cannot be made drugs in the traditional sense. Nrf2 is a transcription factor that stresses oxidative stress. A famous activator, bardoxolone, was acquired by AbbVie for $1 billion many years ago, but it later failed in the CKD trial. However, a recent application for the listing of an analogue, bardoxolone It has been accepted by the FDA. There are both Nrf2 activators and inhibitors in the Vividion product line. Stat3 is also a transcription factor. A few years ago, Sumitomo Pharmaceuticals acquired napabucasin, which is known as a Stat3 inhibitor, but it has failed in several solid tumors in the third stage. WRN is a DNA helicase. The year before last year, two Nature articles were posted in the Moments of Friends and attracted a lot of attention. But this is an enzyme that needs to be combined with DNA to work, and ligand discovery and evaluation are complicated. The E3 linkase, the most intimate target in the Vividion product line, is also a difficult bone. Now there are few other E3 ligands except VHL and CRBN.

Therefore, although the founders possess unique skills, it is still very difficult to conquer these targets. One of the practical goals of Bayer's acquisition is to make it more convenient to build a platform by the water to watch the moon. There is no doubt that these three are the top scientists in the development of small molecule drugs. Even if the target of the product line fails, Bayer may see their latest research results earlier than others. It is said that these people have promised to work closely with Bayer, and the top talents cultivated by these laboratories may also flow more into Bayer's R&D institutions. Bayer, on the other hand, also wants to enter the territory of high-risk, high-return non-medicable targets. This platform may be similar to mRNA in the nucleic acid field. The city value of the two mRNA pioneer companies exceeds 100 billion yuan, so that everyone can see the huge rewards of high-risk disruptive technologies once they succeed. If one or several of these products are successful, it will be a new world of small molecule drugs, and Bayer may also be promoted to Group A.

Reprinted from: Original Articles of U.S. Chinese Medicine Source